Equities analysts expect Allergan plc (NYSE:AGN) to report sales of $3.60 billion for the current quarter, Zacks Investment Research reports. Nineteen analysts have made estimates for Allergan’s earnings. The lowest sales estimate is $3.53 billion and the highest is $3.72 billion. Allergan posted sales of $3.57 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 0.8%. The firm is expected to report its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Allergan will report full year sales of $3.60 billion for the current year, with estimates ranging from $15.03 billion to $15.36 billion. For the next financial year, analysts forecast that the company will post sales of $15.70 billion per share, with estimates ranging from $15.08 billion to $16.38 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Allergan.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The business had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period last year, the business earned $3.90 earnings per share. The firm’s revenue was up 12.0% on a year-over-year basis.
Several equities analysts recently weighed in on the stock. Leerink Swann raised their target price on shares of Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Royal Bank of Canada set a $250.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Sunday, October 29th. They noted that the move was a valuation call. Vetr cut shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 target price for the company. in a research note on Wednesday, January 10th. Wells Fargo & Co reissued an “outperform” rating and issued a $245.00 target price (down from $258.00) on shares of Allergan in a research note on Thursday, November 2nd. Finally, Argus cut shares of Allergan from a “buy” rating to a “hold” rating and decreased their target price for the company from $256.80 to $160.07 in a research note on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $227.23.
Allergan (NYSE:AGN) traded down $1.28 during trading hours on Friday, hitting $159.31. 2,682,218 shares of the company traded hands, compared to its average volume of 3,125,906. Allergan has a twelve month low of $156.00 and a twelve month high of $256.80. The company has a quick ratio of 1.88, a current ratio of 2.04 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $53,050.00, a PE ratio of -13.29, a PEG ratio of 1.16 and a beta of 1.19.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. The ex-dividend date is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.81%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is currently -23.35%.
In other news, insider William Meury sold 58,879 shares of Allergan stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher J. Coughlin bought 10,000 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were purchased at an average cost of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Insiders have bought 17,630 shares of company stock valued at $2,890,057 in the last three months. Insiders own 0.36% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of AGN. Cable Hill Partners LLC raised its stake in Allergan by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. raised its stake in Allergan by 283.7% in the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after purchasing an additional 400 shares in the last quarter. Avestar Capital LLC acquired a new position in Allergan in the fourth quarter valued at about $113,000. Focused Wealth Management Inc raised its stake in Allergan by 4,444.4% in the fourth quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after purchasing an additional 800 shares in the last quarter. Finally, BB&T Investment Services Inc. raised its stake in Allergan by 1,308.2% in the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after purchasing an additional 641 shares in the last quarter. 79.66% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “$3.60 Billion in Sales Expected for Allergan plc (AGN) This Quarter” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/3-60-billion-in-sales-expected-for-allergan-plc-agn-this-quarter.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Get a free copy of the Zacks research report on Allergan (AGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.